Pharmaceuticals

Yuyu Pharma Receives Recognition for Outstanding Company Culture in Korea

SEOUL, South Korea, July 17, 2019 /PRNewswire/ -- Yuyu Pharma has received recognition as a Great Place to Work from the mayor of Jechoen city. The company also supported a recent HeForShe movement sponsored by the city of Jechoen. HeforShe is an UN-led gender equality movement that focuses on th...

2019-07-17 21:00 348

Yuyu Pharma held the campaign for enhancing corporate transparency

SEOUL, South Korea, July 10, 2019 /PRNewswire/ -- Yuyu Pharma, a Korean pharmaceutical company celebrated its third year of implementing Yuyu's compliance management system by inviting senior management to its "Self-Compliance Day" workshop.

2019-07-11 16:43 1450

MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China

ROCKVILLE, Md. and SHANGHAI, July 10, 2019 /PRNewswire/ -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), aChina and U.S....

2019-07-11 04:01 1444

CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed inChina with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritini...

2019-07-10 10:23 6625

Medeon Led and Completed Investments in Panther Orthopedics and Prodeon

TAIPEI, Taiwan, July 8, 2019 /PRNewswire/ -- Medeon Biodesign, Inc. (TPEx: 6499), aTaiwan publicly traded medical device company, is pleased to announce that it recently led and closed two investments, in Panther Orthopedics and Prodeon. Panther Orthopedics is a Silicon Valley startup company pio...

2019-07-08 17:10 8622

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

Novel real world evidence for AFSTYLA® and IDELVION® to be highlighted MELBOURNE, Australia, July 1, 2019 /PRNewswire/ -- Global biotherapeutics leaderCSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor programs at this ...

2019-07-02 06:15 7163

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

GAITHERSBURG, Md., June 25, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces onJune 24, 2019, that the first patient has been dosed in a ...

2019-06-25 22:01 1054

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US andChina while maintain...

2019-06-25 04:00 1075

Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist

OSAKA, Japan, June 24, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi" or "the Company") announces that the Company has concluded an agreement with Eddingpharm (hereafter "Eddingpharm") to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name inJapan: MULPLETA® ...

2019-06-24 22:00 1213

China Jo-Jo Drugstores Enters into Strategic Cooperation Framework Agreement with Zhejiang Medical Insurance Bureau

HANGZHOU, China, June 24, 2019 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider inChina, announced today that...

2019-06-24 20:30 6120

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA

SHANGHAI, June 19, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the trea...

2019-06-19 18:00 2223

Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease

SHANGHAI, June 14, 2019 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone) announced today dosing of the first patient in their Phase II global clinical trials (RSJ10101 and RSJ10201) of SHR0302 in patients with Ulcerative Colitis and Crohn's disease respectively. The Phase II studies ...

2019-06-14 20:30 1364

New Data Shows The Carillon Mitral Contour System® Is Associated With Improvement In Regurgitant Volume In Patients With Increased Mitral Valve Tenting

Data Presentation & Lunch Symposium at TVT2019 Structural Heart Summit CHICAGO, June 13, 2019 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, presented data at the TVT2019 S...

2019-06-13 21:10 3398

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

TAIPEI, Taiwan, June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of concept (PoC) study for its LT3001, a novel drug for the treatment of acute ischemic stroke (AIS) that showed good safety, tolerability...

2019-06-13 20:00 2818

CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA

KFAR SABA, Israel, June 12, 2019 /PRNewswire/ -- CartiHeal, developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints, successfully enrolled the 200th patient in the Agili-C™ IDE pivotal clinical study. Surgery was performed byScott ...

2019-06-12 20:38 1431

Amcor Completes Acquisition of Bemis, Creating the Global Leader in Consumer Packaging

CHICAGO and MELBOURNE, Australia, June 11, 2019 /PRNewswire/ -- Amcor today announces the successful completion of its acquisition of Bemis Company Inc., effective11 June 2019. The combined company will now operate as Amcor plc (Amcor), trading on the New York Stock Exchange under the ticker symb...

2019-06-11 21:46 1786

Collaborative Medicinal Development, LLC Reports that Lead Drug Shows Dose-Dependent Improvement in Parkinson's Disease

MILL VALLEY, California, June 10, 2019 /PRNewswire/ -- Collaborative Medicinal Development LLC ("CMD"), a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases, will report promising results from its phase 1, non-placebo controlled, dose-finding s...

2019-06-10 20:00 1394

Sihuan's Abstracts regarding Clinical Trial Progress of SGLT-2 Inhibitor Selected for Poster Presentation at the American Diabetes Association's Scientific Sessions

HONG KONG, June 10, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular drug manufacturer in China's prescription drug market, announced that three abstracts regarding the clinical trial of the Group's patented innovative drug Janaglif...

2019-06-10 16:28 6255

CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...

2019-06-10 09:30 6541

CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC

SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...

2019-06-05 19:56 6437
12345 ... 36

Week's Top Stories